A. A single test for everyone born between 1945 and 1965, irrespective of HCV risk factors B. Initial testing for everyone, irrespective of HCV risk factors, and then annually for those born from 1945 to 1965 C. Initial testing for everyone born between 1945 and 1965, irrespective of HCV risk factors, and annually for those with HCV risk factors, irrespective of age D. Initial testing for everyone born after 1965, irrespective of risk factors, and then annually based on based on risk factors

A. Every week for the first 4 weeks, and then every 4 weeks for medication refill and measurement of HCV viral load and kidney and liver function tests. B. Every 4 weeks for medication refill, as well as measurement of HCV viral load and kidney and liver function, and then at 12 weeks following completion of therapy C. Every 8 weeks for medication refill and kidney and liver function tests, followed by an HCV viral load measurement at week 24. D. At week 4; if viral load remains positive but is lower, continue testing every 2 weeks until sustained virologic response is achieved.

A. Recommended treatment regimens vary based on several factors including (but not limited to) the patient's HCV subtype, the presence/absence of baseline NS5A resistance-associated variants, pan genotype efficacy, and the presence/absence of cirrhosis. B. Patients infected with genotype 1a may have higher rates of virologic failure than those infected with genotype 1b. C. Patients with HCV genotype 1 infection that cannot be subtyped should be treated as genotype 1a infection. D. HCV genotype 3 is considered the least difficult to treat.

A. Of the DAAs, sofosbuvir has the least potential for DDIs. B. Anti-epileptics may decrease the concentration of all HCV DAAs and compromise efficacy. C. In general, DAAs are CYP3A inhibitors and, therefore, may increase plasma levels of antiretroviral drugs (ie, super-boosting). D. With concomitant anti-mycobacterials, start with low doses and titrate up slowly.

A. Pause the simvastatin and omeprazole during JS's HCV treatment. B. Take omeprazole concomitantly with elbasvir/grazoprevir and offset the dosing of simvastatin and the HCV regimen by 4 hours. C. Continue with JS's current therapies and measure his liver function every 2 weeks. D. Switch his HCV therapy to pegylated-interferon/ribavirin with sofosbuvir.